Drug costs are astronomical – this we know.
But we don’t have a transparent, informed way of calculating – or understanding – the true costs of drug development, argued Dr. Jerry Avorn, a professor of pharmacoeconomics at Harvard University, in this week’s New England Journal of Medicine.